Full Text View
Tabular View
Study Results
Related Studies
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE (PEACE)
This study has been terminated.
( The study was discontinued early, owing to difficulties in recruiting the target sample after seven patients had been recruited. )
Study NCT00687609   Information provided by Eli Lilly and Company

First Received on May 28, 2008.   Last Updated on August 18, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cannabis Abuse
Additional conditions recognized in this trial
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Marijuana Abuse
More general conditions related to this trial
Attention Deficit and Disruptive Behavior Disorders
Dyskinesias
Mental Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Substance-Related Disorders
Interventions listed in this trial
Atomoxetine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services